Tamtam Try Tamtam free
Sartorius logo

Sartorius account plan

Life science innovation and technology

At a glance

Sartorius is a Göttingen-based life science group supplying biopharma research and production, with €3,538.1 million 2025 sales and 14,042 employees.

Sartorius, founded in 1870 and headquartered in Göttingen, Germany, supplies the biopharmaceutical industry and life science research with products to develop and manufacture biotech medications and vaccines, from cell lines and bioreactors to filtration, single-use consumables, lab instruments and bioanalytics. Its customers are pharma and biotech companies, CDMOs, academic institutes and quality-control labs, and more than 90% of sales are generated outside Germany. In 2025 sales revenue was €3,538.1 million (+7.6% in constant currencies), underlying EBITDA €1,051.6 million (margin 29.7%) and relevant net profit €330.7 million, with 14,042 employees at year-end. Sartorius AG is listed in Frankfurt and holds 71.5% of the Euronext-listed Sartorius Stedim Biotech.

Business units

Strategic priorities

Mid-term growth targets
Set at the March 2026 Capital Markets Day: organic growth of 8 to 11% a year from 2027 (Bioprocess 9 to 12%, Lab 5 to 7%) and underlying EBITDA margin expansion of about 50 to 75 basis points a year.
AI in drug development and bioprocessing
The CEO sees AI as the largest potential to shorten development times; Corporate Research works on AI, in-silico simulation and predictive models, and Incucyte's AI image analysis won 3 new top-10 pharma customers this year.
Continuous and intensified manufacturing
The Pionic platform developed with Sanofi, now with Quad & Cross modules for fully integrated continuous downstream processing, sees demand above initial expectations.
Regional growth
Grow in North America, where its share was historically lower, and in Asia, including a new consumables plant in Songdo, South Korea.
Process optimization
Capacity, a resilient supply chain, digital customer interfaces and ERP and CRM digitalization, including the S/4 HANA conversion.

Latest results

In H1 2026 sales revenue was €1,810.9 million, up 7.7% operationally in constant currencies excluding customer compensation for refunded US tariffs, and 6.2% including it. Consumables and services drove growth while equipment and instruments returned to modest growth. Underlying EBITDA rose 3.9% to €547.8 million (margin 30.3%), net profit after minorities rose to €122.2 million and free cash flow increased 70.4% to €207.7 million. Asia | Pacific grew 12.1% on a recovery in China. Guidance for 2026 was confirmed at group sales growth of around 5 to 9% in constant currencies and a margin slightly above 30%.

Investments and deals

Songdo, South Korea
The largest 2025 project and a significant share of 2026 capex: sterile consumables production plus a technology center and labs for Asia | Pacific.
European site expansion
A competence center for cell and gene therapy materials in Freiburg, membrane and filter capacity in Göttingen, nearly doubled cleanroom space in Aubagne and a transfection reagent plant in Illkirch.
Capex programme
Capex was €441.9 million in 2025 (12.5% of sales); 2026 is the last elevated year, with the capex ratio to come down from 2027.
Acquisitions and buyouts
MATTEK acquired July 1, 2025; the remaining 24% of Sartorius CellGenix was bought for about €71.8 million and the remaining stake in Sartorius Automated Lab Solutions for €14.0 million in 2026.
Refinancing
A €500 million, 3.75% bond issued in May 2026 refinanced early the bond maturing in September 2026.

Challenges and risks

Equipment investment restraint
Customers remained reluctant to invest in equipment because of pandemic-era overcapacity, and US reshoring orders are expected mostly in H2 2027 with sales in 2028 and beyond.
US tariffs
A 15% US tariff applies to most EU imports, and tariff refund compensation to customers could reduce 2026 revenue by up to €40 million versus initial assumptions.
Advanced therapies volatility
Delayed late-stage orders at 2 advanced-therapy customers diluted recurring growth, and the gene therapy segment is developing below medium- to long-term expectations.
Leverage
Net debt was €3,761.1 million at June 30, 2026 with leverage of 3.51, after S&P cut the rating to BBB- in 2025.
Competition
Danaher, Merck KGaA and Thermo Fisher compete in both divisions, plus Mettler-Toledo, Eppendorf, Agilent, Becton Dickinson and Revvity in lab products.

What leadership says

“If done right, it might become the biggest transformation in our industry”

Michael Grosse, CEO · CEO interview in the Annual Report 2025, on AI

“Leveraging AI to drive a step change in speed of drug discovery and in productivity or bioprocessing is becoming a must.”

Michael Grosse, CEO · H1 2026 results call, July 23, 2026

“we will not celebrate if we achieve only a 6% growth for 2026.”

Michael Grosse, CEO · Preliminary 2025 results call, February 3, 2026

“We stay committed to our investment-grade rating.”

Florian Funck, CFO · Preliminary 2025 results call, February 3, 2026

Where a supplier can help

AI and data for R&D
The CEO's AI agenda and Corporate Research work on in-silico simulation and predictive models open doors for AI, data and software partners.
Plant build-out and automation
The Songdo plant, Freiburg and Göttingen expansions and elevated 2026 capex point to engineering, cleanroom, automation and equipment suppliers.
ERP, CRM and digital interfaces
The process-optimization priority, including the S/4 HANA conversion, ERP and CRM digitalization and digital customer interfaces, suits IT integrators and software vendors.
Supply chain and logistics
A resilient supply chain is a stated focus, sterilization, packaging and logistics are largely outsourced, and tariffs and Middle East freight costs add pressure.
North American growth
The push to gain share in North America and capture reshoring projects fits commercial, channel and market-access partners.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Sartorius?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Sartorius

What does Sartorius do?

Sartorius supplies the biopharmaceutical industry and life science research with bioprocess equipment, single-use consumables, filtration, cell culture products, lab instruments and bioanalytics.

What is Sartorius' revenue?

2025 sales revenue was €3,538.1 million, up 7.6% in constant currencies, with underlying EBITDA of €1,051.6 million; H1 2026 sales were €1,810.9 million.

How many employees does Sartorius have?

14,042 at the end of 2025 and 14,279 at June 30, 2026.

Who leads Sartorius?

Dr. Michael Grosse has been CEO since July 1, 2025, succeeding Dr. Joachim Kreuzburg; Dr. Florian Funck is CFO.

What is Sartorius' strategy?

Above-market profitable growth through portfolio development, regional growth in North America and Asia and process optimization, targeting 8 to 11% organic growth a year from 2027.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)